Document:

Exhibit
10.1

July
1, 2016

 

David
Koos

Chairman
& CEO

Regen
BioPharma Inc. (RGBP)

4700
Spring St., #304

La
Mesa, CA 91942

 

Delivered:
07/01/2016

Via email to: David Koos david.koos@regenbiopharma.com

 

Dear
David,

 

The
purpose of this investment banking engagement agreement (the "Agreement") is to set forth the terms and conditions pursuant
to which CIM Securities, LLC ("CIM"), a FINRA member in good standing, shall act as exclusive financial advisor and
placement agent for Regen BioPharma Inc. (RGBP, RGBPP) (“Company”), a Nevada Corporation and all affiliates (also
the "Company") and introduce the Company to one or more accredited investors (“Investors”) in connection
to a proposed private placement (the "Private Placement") of equity and / or debt securities (the "Securities")
of the Company for the capital needed to continue research and development on four blocker compounds. However, CIM specifically
acknowledges that the Company has retained Objective Capital Partners, located in San Diego, California, to identify potential
strategic partners for the Company, which could result in an infusion of capital that does not involve the sale of debt or equity
securities. The gross proceeds from the CIM Private Placement or negotiated transactions are proposed to be a $1,000,000 Minimum
Offering and up to $8,000,000 Maximum in gross proceeds on terms that will be mutually agreed upon by both parties. The terms
and final structure of such “best efforts” Private Placement, including the amount, identified use of proceeds, closing
conditions and the specific type of Securities to be issued shall be mutually agreed upon by the Company, CIM and the Investor(s).
However, at this time, both CIM and the Company envision the offering being a convertible debt instrument it is convertible into
shares of the Company’s series A Preferred stock class, with a conversion floor of $0.05 and a conversion ceiling of $0.15.
Additionally, both CIM and the Company will agree that the Minimum raise amount shall be defined as $1,000,000 less the cash in
the Company’s Chase bank accounts on the day that the Private Placement is release into the marketplace. In the event that
the Company has a cash balance in excess of $1,000,000 then both parties agree that the minimum raise amount will have been satisfied.

 

The
parties hereto hereby agree that the Company shall pay to CIM the fees and compensation set forth below if there is any closing
and funding of a debt or equity financing, (including without limitation the Private Placement) for the Company (a "Financing")
within twenty four (24) months of the date of this Agreement with any investors to whom the Company was introduced by CIM, either
directly or indirectly, or whom were contacted by CIM and identified to the Company pursuant to this agreement, regardless of
whether this Agreement was previously terminated.

 

The
Company hereby engages the Advisor on an exclusive basis for the term (“Term”) of this Agreement which shall be for
a period of Six (6) months from the final signature date by the Company’s authorized Officer, and the Advisor hereby agrees
to advise, consult with, and assist the Company in various consulting matters including but not limited to: review of Company
documents, objectives, structure, due diligence, general corporate advice, possible M&A transactions and capitalization structures,
valuations, and capital raising terms. If both Parties wish to continue a new Agreement can be drafted or both Parties can continue
on a month-to-month basis until such time as one Party terminates this Agreement.

 

    	1 

    	 

    

In
the consideration of the services rendered by CIM under this Agreement, the Company agrees to pay CIM the following fees and other
compensation:

 

		(i)	A
                                         Ten Percent (10%) cash fee payable immediately upon the closing and funding of any portion
                                         of any privately placed preferred stock, common stock, convertible debt or convertible
                                         preferred stock, or any other form of equity–linked securities. Additionally, there
                                         will be a five year cashless exercise warrants from the date of Closing the Transaction
                                         equal to Ten Percent (10%) of the common shares or common share equivalents issued or
                                         to be issued in this or any other form of equity-linked financing with an exercise price
                                         equal to the offering or conversion price in such financing. If Company brings in any
                                         accredited investors during this agreement term period though the close of the Offering,
                                         the Company shall pay CIM Two and One Half Percent (2.5%); These reduced banker fees
                                         and warrants would apply to the Minimum Offering as well and any additional investors
                                         after the Minimum is met.

		(j)	A
                                         Five Percent (5%) cash fee payable immediately upon the closing and funding of any subordinated
                                         or mezzanine debt financing, including any unitranche or senior “stretch”
                                         term loans or credit facilities along with Five Percent (5%) warrants priced as the same
                                         as the investors would get for their warrants or shares attached to the debt securities;

		(k)	A
                                         Three Percent (3%) cash fee payable immediately upon the closing and funding of any senior
                                         debt financing, including any asset based revolving credit facilities along with Three
                                         Percent (3%) of the warrants at the fair market value of the Company at the time of the
                                         Transaction (price to be determined by mutual agreement);

		(l)	A
                                         Cash Fee equal to Five Percent (5%) of the Aggregate Value of any M&A transaction
                                         sourced by CIM including all equity, mezzanine, senior debt, and any additional monies
                                         paid out at closing to the Company or target Acquisition.

		(m)	A
                                         Cash Fee equal to Five Percent (5%) for any Joint Venture, Strategic Partnership, or
                                         Gross Revenue share on any Transactions brought by CIM to Company.

		(n)	A
                                         non-refundable and non-contestable upfront retainer of $12,500 payment due, upon signing
                                         of this Agreement, to CIM Securities, LLC. Payment should be in the form of a wire payment
                                         to CIM (wire instructions will be provided when signed by Company), and the Company will
                                         hereby give CIM Securities, and its designees a further engagement fee in the form of
                                         a right to purchase warrants (“Engagement Warrants”) for 150,000 Preferred
                                         Shares with either a cash exercise price of $1,000 for the shares or via cashless exercise
                                         provision. CIM will purchase this Engagement Warrants from the Company for a nominal
                                         price of $100 for the warrant agreement.

		(o)	All
                                         amounts payable (not to include the nonrefundable retainer) hereunder shall be paid to
                                         CIM out of an escrow account here in the U.S. by an FDIC Insured Banking Institution
                                         that is acceptable to CIM at the closing or by such other means acceptable to CIM, along
                                         with any out of pocket expenses incurred in carrying out any Due Diligence and Marketing
                                         expenses of the Financing. Company and CIM may choose to do a best efforts with a “no
                                         minimum offering” at which time there would be no need for an Escrow Account; but
                                         Company agrees not to cash any check or to take any wire funds from an Investor until
                                         fully accepted by CIM Chief Compliance Officer Sinh Ly;

		(p)	If
                                         during the Term of this Agreement the Company shall source an investor then the Company
                                         will agree to pay CIM Securities a fee equal to 100% of both the cash fees and warrants
                                         compensation as outlined in the same manner for both (a) thru (f) of this section. Should
                                         the Company source any of the Investors on its own efforts (excluding other FINRA member
                                         firms) then it would only pay CIM 50% of it fees and warrants in paragraphs (a) thru
                                         (f); and if the Company has a current “carve out” list that it is talking
                                         to right now and would like to provide it to us on the date of this Agreement being signed
                                         then CIM would agree to take only 25% of its fees and warrants as outlined in paragraphs
                                         (a) thru (f) which would be attached to this Agreement in Exhibit A hereto, if any.

 

    	2 

    	 

    

This
Agreement shall be governed by and construed in accordance with the laws of the State of Colorado, without regard to conflicts
of law principles. Any dispute arising out of this agreement shall be adjudicated in the courts in the State of Colorado or in
the federal court sitting in the Arapahoe County district of Colorado, and each of the parties hereto agrees that service of process
upon it by registered or certified mail at its address set forth here in shall be deemed adequate and lawful. The Parties may
alternately agree to move any litigation to Arbitration in Arapahoe County.

 

The
Company agrees to not substantially change their business model after signing this agreement. Changing the business model substantially
may result in CIM terminating this agreement and engagement fees will not be returned. If a change must be made, CIM has the right
to approve the change and move forward as the financial advisor with a revised engagement agreement or terminate this agreement
with no refund of fees paid by the Company.

 

The
Company and CIM hereby agree to the terms and conditions of the Indemnification Agreement attached hereto as Appendix A with the
same force and effect as if such terms and conditions were set forth at length herein.

 

This
Agreement constitutes the entire understanding and agreement between the parties hereto with respect to its subject matter and
there are no agreements or understanding with respect to the subject matter hereof which are not contained in this Agreement.
This Agreement may be modified only in writing signed by the party to be charged hereunder.

 

If
the foregoing correctly sets forth our agreement, please confirm this by signing and returning to us the duplicate copy of this
letter. This Engagement Agreement Offer will expire if not signed by Company by July 8, 2016 at 5 pm Pacific Time and shall then
be considered null and void.

 

	 	 	Best Regards,
	 	 	 
	 	By:	/s/ Sinh Ly
	 	 	Sinh Ly
	 	 	Managing Director

 

	ACCEPTED AND AGREED TO:	 	 
	Regen BioPharma Inc.	 	 
	 	 	 	 
	By:	/s/ David Koos	Date:	7/1/2016
	 	David Koos	 	 
	 	Chairman & CEO	 	 

 

    	3 

    	 

    

APPENDIX
A

 

INDEMNIFICATION
AGREEMENT

 

 

Appendix
A to Letter of Engagement Agreement (the "Agreement"), dated June 26, 2016, by and between Regen BioPharma Inc., its
affiliates and subsidiaries (collectively, the "Company") and CIM Securities, LLC ("CIM").

 

The
Company agrees to indemnify and hold CIM and its affiliates, control persons, directors, officers, employees and agents (each
an "Indemnified Person") harmless from and against all losses, claims, damages, liabilities, costs or expenses, including
those resulting from any threatened or pending investigation, action, proceeding or dispute whether or not CIM or any such other
Indemnified Person is a party to such investigation, action, proceeding or dispute, arising out of CIM's entering into or performing
services under this Agreement, or arising out of any matter referred to in this Agreement. This indemnity shall also include CIM's
and/or any such other Indemnified Person's reasonable attorneys' and accountants' fees and out-of-pocket expenses incurred in
such investigations, actions, proceedings or disputes which fees, expenses and costs shall be periodically reimbursed to CIM and/or
to any such other Indemnified Person by the Company as they are incurred; provided, however, that the indemnity herein set forth
shall not apply to an Indemnified Person where a court of competent jurisdiction has made a final determination that such Indemnified
Person acted in a grossly negligent manner or engaged in willful misconduct in the performance of the services hereunder which
gave rise to the loss, claim, damage, liability, cost or expense sought to be recovered hereunder (but pending any such final
determination the indemnification and reimbursement provisions hereinabove set forth shall apply and the Company shall perform
its obligations hereunder to reimburse CIM and/or each such other Indemnified Person periodically for its, his or their fees,
expenses and costs as they are incurred). The Company also agrees that no Indemnified Person shall have any liability (whether
direct or indirect, in contract or tort or otherwise) to the Company for or in connection with any act or omission to act as a
result of its engagement under this Agreement except for any such liability for losses, claims, damages, liabilities or expenses
incurred by the Company that is found in a final determination by a court of competent jurisdiction to have resulted from such
Indemnified Person's gross negligence or willful misconduct.

 

If
for any reason, the foregoing indemnification is unavailable to CIM or any such other Indemnified Person or insufficient to hold
it harmless, then the Company shall contribute to the amount paid or payable by CIM or any such other Indemnified Person as a
result of such loss, claim, damage or liability in such proportion as is appropriate to reflect not only the relative benefits
received by the Company and its shareholders on the one hand and CIM or any such other Indemnified Person on the other hand, but
also the relative fault of the Company and CIM or any such other Indemnified Person, as well as any relevant equitable considerations;
provided that in no event will the aggregate contribution by CIM and any such other Indemnified Person hereunder exceed the amount
of fees actually received by CIM pursuant to this Agreement. The reimbursement, indemnity and contribution obligations of the
Company hereinabove set forth shall be in addition to any liability which the Company may otherwise have and these obligations
and the other provisions hereinabove set forth shall be binding upon and inure to the benefit of any successors, assigns, heirs
and personal representatives of the Company, CIM and any other Indemnified Person.

 

    	4 

    	 

    

 

 

(INDEMNIFICATION
AGREEMENT SIGNATURE PAGE)

 

 

The
terms and conditions hereinabove set forth in this Appendix A shall survive the termination and expiration of this Agreement and
shall continue indefinitely thereafter.

 

	 	 	Best Regards,
	 	 	 
	 	By:	/s/ Sinh Ly
	 	 	Sinh Ly
	 	 	Managing Director

 

	ACCEPTED AND AGREED TO:	 	 
	Regen BioPharma Inc.	 	 
	 	 	 	 
	By:	/s/ David Koos	Date:	7/1/2016
	 	David Koos	 	 
	 	Chairman & CEO	 	 

 

    	5Exhibit

IN MAKING AN INVESTMENT DECISION, YOU MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER OF THE SECURITIES REFERRED TO HEREIN, INCLUDING THE MERITS AND RISKS INVOLVED. THE SECURITIES OFFERED HEREBY HAVE NOT BEEN RECOMMENDED BY ANY FEDERAL OR STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY. FURTHERMORE, THE FOREGOING AUTHORITIES HAVE NOT CONFIRMED THE ACCURACY OR DETERMINED THE ADEQUACY OF ANY OFFERING MATERIALS OR THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
 
THE SECURITIES REFERRED TO HEREIN ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. YOU SHOULD BE AWARE THAT YOU MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.

EUROSITE POWER INC.

Convertible Note Amendment and Conversion Agreement

June [  ], 2016
EuroSite Power Inc.
45 First Avenue
Waltham, MA 02451
Ladies and Gentlemen:
1.  Background.  The undersigned (the “Noteholder”) is the owner of a 4% Senior Convertible Note Due 2018 (the “Note”) issued by EuroSite Power Inc. (“EUSP”) in the aggregate principal amount set forth on the signature page and issued pursuant to the terms of the Noteholders Agreement entered into between the Noteholder and EUSP (the “Noteholders Agreement”). Noteholders executing a Convertible Note Amendment and Conversion Agreement (each, an “Amendment and Conversion Agreement”) similar to this one are referred to as the “Noteholders” and the aforesaid Notes of EUSP held by the Noteholders are referred to herein as the “EUSP Notes.” Interest accrued and unpaid on the Note through the date hereof (the “Interest”), is as set forth on the signature page hereof.
In consideration of the foregoing, and such other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and for the good and valuable consideration hereinafter set forth, the parties hereto do hereby enter into this Amendment and Conversion Agreement.
2.  Amendment. The Noteholder and EUSP have agreed to amend the Noteholders Agreement to modify the term “Initial Conversion Rate” therein to provide that each $1,000 principal amount of and unpaid Interest on the Notes shall be convertible into newly issued shares of EUSP common stock, $0.001 par value per share (the “EUSP Shares”) at a conversion price of $0.54 per EUSP Share (the “Conversion Price”), as set forth on the signature page hereof, and which Conversion Price shall be used to calculate the current market value of a fractional share.  In addition, the Noteholders Agreement is hereby amended to permit the conversion of the EUSP Notes as of the date set forth hereinabove.  
3.  Conversion of EUSP Notes.
a.Conversion. The Noteholder hereby agrees to and does hereby provide notice of conversion of the entire principal and Interest on the Note owned by it into newly issued EUSP Shares at a purchase price per share of $0.54 as set forth on the signature page hereof and agrees to accept such EUSP Shares in full satisfaction of the obligations of EUSP and American DG Energy, 

Inc. pursuant to the terms of the Noteholders Agreement and the Notes.  The Noteholder shall furnish such appropriate endorsements and transfer documents if required by EUSP and pay any transfer or similar tax, if required as provided in the Noteholders Agreement. 
b.Deliveries. As soon as practical after the execution of this Amendment and Conversion Agreement by the parties, the Noteholder agrees to deliver to EUSP for cancellation all of the Notes owned by it.  Upon delivery to EUSP of the Notes held by the Noteholder and executed copies of a similar Amendment and Conversion Agreement by at least a majority in aggregate principal amount of the outstanding EUSP Notes, EUSP agrees to cause its transfer agent to issue and deliver to the Noteholder the EUSP Shares issuable on the conversion of such Notes and shall deliver to the Noteholder cash in lieu of any fractional shares to be issued upon the conversion of such Note, the parties acknowledging and agreeing that no cash dividends have been paid by EUSP from the date of original issue of the Note to the date hereof.
4.  Representations and Warranties.
a.EUSP. EUSP hereby confirms that its representations, warranties and agreements in the subscription agreement and other documents pursuant to which the original EUSP Notes were issued continue to be true and correct as if made on the date hereof and as if made with respect to the securities being issued pursuant hereto, except that with respect to such representations and warranties that speak as of a particular date, no material adverse change has occurred making such representations and warranties untrue or incorrect in any material respect as of the date hereof.  Without limiting the foregoing, EUSP represents and warrants that the EUSP Shares issuable upon conversion of the Notes have been duly and validly authorized and, when issued pursuant hereto, the EUSP Shares will be validly issued, fully paid and nonassessable.
b.The Noteholder. The Noteholder hereby confirms that the Noteholder’s representations, warranties and agreements in the subscription agreement and other documents pursuant to which the Noteholder purchased its Notes are true and correct as of the date hereof. Without limiting the foregoing, the Noteholder represents and warrants that the Noteholder is an “accredited investor” as defined by Rule 501 under the Securities Act of 1933, as amended (the “Securities Act”), and is capable of evaluating the merits and risks of an investment in the EUSP Shares and has the ability and capacity to protect its interests.  The Noteholder acknowledges and understands that the EUSP Shares are being purchased for investment purposes and not with a view to distribution or resale, nor with the intention of selling, transferring or otherwise disposing of all or any part thereof for any particular price, or at any particular time, or upon the happening of any particular event or circumstances, except selling, transferring, or disposing the EUSP Shares made in full compliance with all applicable provisions of the Securities Act, the rules and regulations promulgated by the Securities and Exchange Commission thereunder, and applicable state securities laws.  The Noteholder further understands that the EUSP Shares being acquired by the Noteholder hereunder may only be transferred or resold by way of registration of such Shares for resale under the Securities Act, or an applicable exemption under the Securities Act.  The EUSP Shares being delivered will contain a restrictive legend to that effect. 
5.  Expenses. Each party hereto shall each bear its own expenses incurred in connection with this transaction.
6.  Miscellaneous.
a. Notices. When any notice is required or authorized hereunder, such notice shall be given in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed electronic mail if sent during normal business hours of the recipient, and if not sent during normal business hours, then on the next business day so long as receipt is confirmed, (iii) five days after having been sent by registered or certified mail (or regular mail if registered or certified mail is unavailable in the country of the recipient), (iv) if sent within 

the U.S., one business day after deposit with a recognized overnight courier, specifying next business day delivery, with written verification of receipt or (v) if sent from the U.S. to an address outside the U.S. or if sent from outside the U.S. to an address within the U.S., five business days after deposit with an internationally recognized courier service specifying that delivery be made within five business days with written verification of receipt. All notices and other communications shall be sent if sent to the Noteholder, to the business address or email address of the Noteholder set forth on the signature page to this Amendment and Conversion Agreement, as it may subsequently change by notice from the Noteholder; and
	
		
	If to EuroSite, to:
	EuroSite Power, Inc.

	 
	45 First Avenue

	 
	Waltham, MA 02451

	 
	Attention:  Chief Financial Officer

	 
	Email: bonnie.brown@americandg.com

	 
	 

	With a copy to:
	Somertons, PLLC

	 
	1050 17th Street, N.W., Suite 600

	 
	Washington, DC 20036

	 
	Attention: Kathleen L. Cerveny, Esq.

	 
	Email: kathleen.cerveny@somertons.com

Such notices or communications shall be effective when received. If a notice or communication to Noteholder is sent in the manner provided above, it is duly given, whether or not the addressee receives it. EuroSite by notice to the Noteholder may designate additional or different addresses for subsequent notices or communications.
a.Successors and Assigns. This Amendment and Conversion Agreement shall be binding upon the heirs, executors, administrators, successors and assignees of the Noteholder.
b.Choice of Law. This Amendment and Conversion Agreement shall be governed by, and construed in accordance with, the internal laws of the State of New York and, to the extent it involves any United States federal statute or regulations, in accordance therewith.
c.Consent to Jurisdiction. The parties hereby consent and submit to the exclusive jurisdiction of the state and federal courts in New York City with respect to all disputes arising in connection with this transaction.
d.Survival of Representations. The parties agree that all of the warranties, representations, acknowledgments, confirmations, covenants and promises made in this Amendment and Conversion Agreement shall survive its execution and delivery.
e.Counterparts. This Amendment and Conversion Agreement may be executed in any number of counterparts each of which shall be deemed an original and which, taken together, shall form one and the same agreement. Execution and delivery of this Amendment and Conversion Agreement may be evidenced by a scan/.pdf of the executed document sent by email.
f.Integration. This Amendment and Conversion Agreement is the complete and exclusive agreement between the parties with regard to the subject matter hereof and supersedes any and all prior discussions, negotiations and memoranda related hereto.
g.Severability. If any provision of this Amendment and Conversion Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Amendment and Conversion Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable provision that is a reasonable 

substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Amendment and Conversion Agreement. 

[Signature Page Follows]

The undersigned Noteholder and EUSP hereby execute this Convertible Note Amendment and Conversion Agreement as of the date first set forth above
	
	
	 

	 Amount of Notes being converted into newly issued EUSP Shares at $0.54 per share

 Amount of Interest on Notes being converted into newly issued EUSP Shares at $0.54 per share	
	
	 

	 Number of EUSP Shares issuable at $0.54 per share upon conversion of the Notes and Interest

	 

	 Noteholder Name

 Noteholder Signature

 	
		
	 Business Address of Noteholder

 

	AGREED: 
EUROSITE POWER INC. 

	By:
	 

	 
	 Signature

	Name:
	 

	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}]]